Privosegtor not checked

Oculis · OCS-05

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
1 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Optic Neuritis
Main trialPhase 3
“The goal of this clinical trial is to evaluate the safety and efficacy of privosegtor, a neuroprotective candidate, in patients diagnosed with optic neuritis (ON). Researchers will compare privosegtor and the standard of care (methylprednisolone) to a placebo and standard of care (methylprednisolone).”In the company’s words, NCT07623668 on ClinicalTrials.gov
Other names
OCS-05

Other drugs for Optic Neuritis

All 11 drugs for Optic Neuritis

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Dec 2027 Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research
Phase 2Completed 16 Sep 2024 OCS-05 in Patients With Optic Neuritis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Privosegtor

Following is part of Solo: you see every change to Privosegtor the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in